Show simple item record

dc.contributor.authorAijaz, Ayesha
dc.contributor.authorLi, Matthew
dc.contributor.authorSmith, David
dc.contributor.authorKhong, Danika
dc.contributor.authorLeBlon, Courtney
dc.contributor.authorFenton, Owen S.
dc.contributor.authorOlabisi, Ronke M.
dc.contributor.authorLibutti, Steven
dc.contributor.authorTischfield, Jay
dc.contributor.authorMaus, Marcela V.
dc.contributor.authorDeans, Robert
dc.contributor.authorBarcia, Rita N.
dc.contributor.authorAnderson, Daniel Griffith
dc.contributor.authorRitz, Jerome
dc.contributor.authorPreti, Robert
dc.contributor.authorParekkadan, Biju
dc.date.accessioned2019-08-09T19:59:11Z
dc.date.available2019-08-09T19:59:11Z
dc.date.issued2018-06
dc.date.submitted2017-07
dc.identifier.issn2157-846X
dc.identifier.urihttps://hdl.handle.net/1721.1/121979
dc.description.abstractThe achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use.en_US
dc.language.isoen
dc.publisherSpringer Science and Business Media LLCen_US
dc.relation.isversionofhttp://dx.doi.org/10.1038/s41551-018-0246-6en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourcePMCen_US
dc.titleBiomanufacturing for clinically advanced cell therapiesen_US
dc.typeArticleen_US
dc.identifier.citationAijaz, Ayesha et al. "Biomanufacturing for clinically advanced cell therapies." Nature Biomedical Engineering 2, 6 (June 2018): 362–376 © 2018 The Author(s)en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Institute for Medical Engineering and Scienceen_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.contributor.departmentDavid H. Koch Institute for Integrative Cancer Research at MITen_US
dc.relation.journalNature Biomedical Engineeringen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2019-08-09T14:00:45Z
dspace.date.submission2019-08-09T14:00:47Z
mit.journal.volume2en_US
mit.journal.issue6en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record